Whitepaper/App Note

Whitepaper: Bioanalytical support in the development of biologics

Posted: 1 April 2016 | | 2 comments

In this publication Imperacer® case studies demonstrate the advantage of broad assay range combined with excellent sensitivity for several Biologics on their way from R&D to clinics…

Therapeutic antibodies and other biotherapeutic macromolecule drugs (Biologics) often pose challenges in bioanalytical support. Safety and potency considerations frequently demand low dosing in dose-escalation trials and in consequence very sensitive ligand-binding assays (LBA) for PK support, even at late time points and despite fast drug clearance. In addition a broad assay range with high upper limit of quantification is particularly favorable to cover PK analytics at early time points, for high dosing or during Tox evaluation. Ideally a bioanalytical method covers the full drug concentration range to enable PK profiling during the complete drug development program. 

In this publication Imperacer® case studies demonstrate the advantage of broad assay range combined with excellent sensitivity for several Biologics on their way from R&D to clinics.

This whitepaper is restricted to logged-in members. Login or subscribe free to read it.


Related organisations

Send this to a friend